Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases
Stem cell-based therapies can potentially reverse organ dysfunction and diseases but the removal of impaired tissue and reactivation of the program leading to organ regeneration pose major challenges. In mice, a four-day fasting mimicking diet (FMD) induces a step-wise expression of Sox17 and Pdx-1, resembling that observed during pancreatic development and followed by Ngn3-driven generation of insulin-producing β-cells. FMD cycles restore insulin secretion and glucose homeostasis in both a type 2 and type 1 diabetes mouse models. In human type 1 diabetes pancreatic islets, fasting conditions reduce PKA and mTOR activity and induce Sox2 and Ngn3 expression and insulin production. The effects of the FMD are reversed by IGF-1 treatment and recapitulated by PKA and mTOR inhibition. These results indicate that a FMD promotes the reprogramming of pancreatic cells to restore insulin generation in islets from T1D patients and reverse both T1D and T2D phenotypes in mouse models.
1. A method for promoting pancreatic β-cell regeneration comprising:
identifying a subject in need of human pancreatic β-cell regeneration; and
administering a fasting mimicking diet (FMD) for a predetermined period of time and administering a Protein Kinase A (PKA) inhibitor and administering a Tor inhibitor to the subject to promote pancreatic β-cell regeneration, wherein the fasting mimicking diet provides:
less than 40 grams of sugar for day 1;
less than 30 grams of sugar for days 2 to 5 and any remaining days;
less than 28 grams of protein for day 1;
less than 18 grams of protein for days 2 to 5 and any remaining days;
20-100 grams of monounsaturated fats for day 1;
6-30 grams of polyunsaturated fats for day 1;
2-12 grains of saturated fats for day 1;
10-50 grams of monounsaturated fats for days 2 to 5 and any remaining days;
3-15 grams of polyunsaturated fats for days 2 to 5 and any remaining days;
1-30 grams of saturated fats for days 2 to 5, or any remaining days; and
a micronutrient composition on each day and any remaining days, and wherein the PKA inhibitor and/or the Tor inhibitor is select from the group consisting of an antibody, antagonist or small molecule which blocks IGF-1R, rapamycin which inhibits mTOR, H89 which inhibits PKA, and combinations thereof.
2. The method of claim 1 the subject is diagnosed with diabetes type 1 or diabetes type 2.
3. The method of claim 1 wherein somatic cell dedifferentiation and/or reprogramming is promoted.
4. The method of claim 1 wherein gastrointestinal cell dedifferentiation and/or reprogramming is promoted.
5. The method of claim 1 wherein the fasting mimicking diet promotes muscle rejuvenation associated with stem cell generation.
6. The method claim 5 wherein insulin resistance is decreased.
7. The method of claim 5 wherein hyperglycemia is reduced.
8. The method of claim 1 wherein the predetermined period of time is 5 to 10 days.
9. The method of claim 1 wherein the fasting mimicking diet provides:
8-25 kcal per kilogram body weight for each diet day:
less than 30 grams of sugar for each diet day;
less than 18 grams of protein for each diet day; and
9-30 grams of monounsaturated fats for each diet day, 2.5-9 grams of polyunsaturated fats for each diet day and 1-10 grams of saturated fats for each diet day.
10. The method of claim 1 wherein the fasting mimicking diet provides:
5-8 kcal per kilogram body weight for each diet day;
less than 20 grams of sugar for each diet day;
less than 12 grams of protein for each diet day; and
6.5-10 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-4 grams of saturated fats for each diet day.
11. The method of claim 1 wherein the fasting mimicking diet provides:
0-3 kcal per kilogram body weight for each diet day;
less than 5 grams of sugar for each diet day;
less than 3 grams of protein for each diet day; and
less than 2.5 grams of monounsaturated fats for each diet day, less than 1 grams of polyunsaturated fats for each diet day and less than 1 grams of saturated fats for each diet day.
12. The methond of claim 1 wherein the fasting mimicking diet is administered from a diet package, the diet package comprising:
a first set of rations for a first diet to be administered for a predetermined time period to the subject with administration schedule, the first diet providing:
less than 40 grams of sugar for day 1;
less than 30 grams of sugar for days 2 to 5 and any remaining days;
less than 28 grams of protein for day 1;
less than 18 grams of protein for days 2 to 5 and any remaining days;
20-100 grams of monounsaturated fats for day 1;
6-30 grams of polyunsaturated fats for day 1;
2-12 grams of saturated fats for day 1;
10-50 grams of monounsaturated fats for days 2 to 5 and any remaining days;
3-15 grams of polyunsaturated fats for days 2 to 5 and any remaining days;
1-12 grams of saturated fats for days 2 to 5, or any remaining days; and
a micronutrient composition on each day and any remaining days; and
instructions for administering the diet package to the subject for promoting pancreatic β-cell regeneration and somatic cell reprogramming, the instructions including the administration schedule.
13. The method of claim 12 wherein the fasting mimicking diet provides:
8-10 kcal per kilogram body weight for each diet day:
less than 30 grams of sugar for each diet day;
less than 18 grams of protein for each diet day; and
9-15 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1-5.5 grams of saturated fats for each diet day.
14. The method of claim 12 wherein the fasting mimicking diet provides:
5-8 kcal per kilogram body weight for each diet day;
less than 20 grams of sugar for each diet day;
less than 12 grams of protein for each diet day; and
6.5-10 grams of monounsaturated fats for each diet day, 2.5-4.5 grams of polyunsaturated fats for each diet day and 1.5-4 grams of saturated fats for each diet day.
15. The method of claim 12 wherein the fasting mimicking diet provides:
0-3 kcal per kilogram body weight for each diet day;
less than 5 grams of sugar for each diet day;
less than 3 grams of protein for each diet day; and
less than 2.5 grams of monounsaturated fats for each diet day, less than 1 grams of polyunsaturated fats for each diet day and less than 1 grams of saturated fats for each diet day.
16. The method of claim 12 further comprising a second set of rations for a second diet to be administered to the subject for a second time period, the second diet providing an overall calorie consumption that is within 10 percent of a subject's normal calorie consumption for 25 to 26 days following the first diet.
17. The method of claim 12 wherein the first set of rations provide 400-800 mg of calcium per day for days 1-5; 7.2-14.4 mg of iron per day for days 1-5; 200-400 mg of magnesium per day for days 1-5; 1-2 mg of copper per day for days 1-5; 1-2 mg of manganese per day for days 1-5; and 3.5-7 mcg of selenium per day for days 1-5.
18. The method of claim 12 wherein the first set of rations provide 2-4 mg of Vitamin B1 per day for days 1-5; 2-4 mg of Vitamin B2 per day for days 1-5; 20-30 mg of Vitamin B3 per day for days 1-5; 1-1.5 mg of Vitamin B5 per day for days 1-5; 2-4 mg of Vitamin B6 per day for days 1-5; 240-480 mcg of Vitamin B9 per day for days 1-5; 600-1000 IU of Vitamin D per day for days 1-5; 14-30 mg of Vitamin E per day for days 1-5; over 80 mcg of Vitamin K per day for days 1-5; and 16-25 mcg Vitamin B12 are provided during the predetermined time period.
19. The method of claim 1 wherein the PKA inhibitor is select from the group consisting of H89, antibodies which blocks IGF-IR, PKA siRNA, and combinations thereof.
20. The method of claim 1 wherein the PKA it inhibitor is H89.
21. The method of claim 1 wherein the PKA inhibitor is an antibody which blocks IGF-IR.
22. The method of claim 1 wherein the Tor inhibitor is rapamycin or an antibody which blocks IGF-IR.
23. The method of claim 1 wherein the Tor inhibitor is rapamycin.
24. The method of claim 1 wherein the Tor inhibitor is rapamycin and the PKA inhibitor is H89.
25. The method of claim 11 wherein the first set of rations provides 600 mg of Docosahexaenoic acid (DHA, algae-derived) during the predetermined time period.
26. The method of claim 12 further comprising a component having Vitamin A in an amount of 900-1600 IU; Ascorbic Acid in an amount of 10-20 mg; calcium carbonate in an amount of 60-100 mg; ferrous fumarate in an amount of 3-6 mg; cholecalciferol in an amount of 0.001-0.005 mg; dl-alpha tocopheryl acetate in an amount 3-7 mg; phytonadione in an amount of 0.1-0.04 mg; thiamine mononitrate in an amount of 0.15-0.5 mg; riboflavin in an amount 0.2-0.6 mg; and niacinamide in an amount of 3-7 mg.
27. The method of claim 26 further comprising a component having calcium pantothenate in an amount of 1.5-4.0 mg; pyridoxine hydrochloride in an amount of 0.3-0.7 mg; biotin in an amount of 0.01-0.02 mg; folic acid in an amount of 0.07-0.14 mg; cyanocobalamin in an amount of 0.001-0.002 mg; chromium picolinate in an amount of 0.014-0.022 mg; cupric sulfate in an amount of 0.18-0.32 mg; potassium iodide in an amount of 0.03-0.045 mg; magnesium oxide in an amount of 20-32 mg; manganese sulfate of 0.3-0.7 mg; sodium molybdate in an amount of 0.014-0.023 mg; sodium selenate in an amount of 0.014-0.023 mg; and zinc oxide in an amount of 3-5 mg.